Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06665971 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Effect of Dupilumab on the Muscle Function of the Esophagus (food Pipe) in Participants with Eosinophilic Esophagitis (EoE)

StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated December 11, 2024 (before its estimated September 15, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Trial status: Not Yet Recruiting to Recruiting Secondary endpoints revised (3) · Site details revisedv3 Show 2 more changesShow less
    • Secondary endpoints revised (3)
    • Site details revised

    See this version in full on ClinicalTrials.gov ↗

  2. Secondary endpoints: details revised at 1 of 3 entries Study title revised · Eligibility criteria expanded, about 2 words · Study description expanded, about 3 wordsv2 Show 3 more changesShow less
    • Study title revised
    • Eligibility criteria expanded, about 2 words
    • Study description expanded, about 3 words

    See this version in full on ClinicalTrials.gov ↗

  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this study is to research Dupilumab, an FDA approved medication in treating patients diagnosed with Eosinophilic esophagitis (EoE). The drug works by controlling allergic inflammation of the esophagus. The esophagus is a food pipe that transfers food from the mouth into the stomach. Participants with EoE have dysfunction of the muscle of the esophagus (impaired peristalsis) that is not favorable for the transport function. Main question this study aims to answer is: Whether Dupilumab helps improve muscle activity of the esophagus in participants with EOE? Participants will: Take Dupilumab every week for 12 weeks. Visit the clinic before and after starting the medication. Keep a diary of symptoms.
Trial Details
NCT Number NCT06665971
Lead Sponsor University of California, San Diego
Collaborators: Regeneron Pharmaceuticals
Conditions Eosinophilic Esophagitis (EoE)
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov